Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.04%, reaching 25.65 CNY per share, with a trading volume of 267 million CNY and a turnover rate of 5.12%, resulting in a total market capitalization of 5.39 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business involves centralized marketing and service for medical testing, as well as the agency and independent research, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of the top ten circulating shareholders of Selys Medical, data shows that a fund under Caitong Fund ranks among the top ten shareholders. The Caitong Advantage Industry Rotation Mixed A Fund (011201) entered the top ten shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares [2] - The Caitong Advantage Industry Rotation Mixed A Fund (011201) was established on February 9, 2021, with a latest scale of 536 million CNY. Year-to-date returns are 19.74%, ranking 4636 out of 8167 in its category; the one-year return is 22.47%, ranking 4803 out of 8010; and since inception, it has a loss of 27.14% [2]

Group 1 - The core viewpoint of the news is that Sely Medical's stock has increased by 5.02%, reaching a price of 29.89 yuan per share, with a trading volume of 3.09 billion yuan and a turnover rate of 5.02%, resulting in a total market capitalization of 62.81 billion yuan [1] - Sely Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Sely Medical's main business is as follows: IVD business accounts for 39.91%, SPD business accounts for 38.01%, and pure sales account for 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under Caitong Fund ranks among the top shareholders. Caitong Advantage Industry Rotation Mixed A (011201) entered the top ten circulating shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares. The estimated floating profit today is approximately 920,100 yuan [2] - Caitong Advantage Industry Rotation Mixed A (011201) was established on February 9, 2021, with a latest scale of 536 million yuan. Year-to-date return is 27.92%, ranking 2916 out of 8174 in its category; the one-year return is 47.03%, ranking 3325 out of 7981; and since inception, it has a loss of 22.16% [2]

Core Viewpoint - The AI Fund Advantage Industry Rotation Mixed A (011201) reported a profit of 7.89 million yuan for Q1 2025, with a net value growth rate of 1.38% and a fund size of 526 million yuan as of the end of Q1 2025 [2][16]. Fund Performance - As of April 24, the fund's unit net value was 0.59 yuan, with a near-term performance showing a three-month return of -7.82%, a six-month return of -10.78%, a one-year return of -1.53%, and a three-year return of -26.86% [2][4]. - The fund's Sharpe ratio over the past three years was -0.0678, ranking 179 out of 238 comparable funds [9]. - The maximum drawdown over the past three years was 48.59%, with the largest single-quarter drawdown occurring in Q1 2024 at 25.23% [11]. Investment Strategy - The fund manager indicated a focus on several key areas for the next quarter, including: - **Biopharmaceuticals**: Anticipating growth in medical demand and payment capabilities, with a focus on innovative drugs and medical devices that are less affected by hospital sales [3]. - **Communications and Semiconductors**: Expecting significant growth in computing power driven by AI applications, with investment opportunities in domestic supply chains for optical modules and PCBs [3]. - **Non-ferrous Metals**: Favoring gold and copper as beneficiaries of anticipated U.S. interest rate cuts and domestic economic recovery [3]. Fund Holdings - The fund has a high concentration of holdings, with the top ten stocks including companies like Ruikeda, Sanofi, and Tencent Holdings as of Q1 2025 [19]. Fund Positioning - The average stock position over the past three years was 90.22%, higher than the comparable average of 85.88%, with a peak of 94.56% in mid-2022 [14].